BioSpace News Archive

MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share.

Life Sciences British Columbia (LSBC) announces the 31 companies presenting to the 6th annual Invest in BC presented by Lumira Ventures on November 3 and 4, 2021

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.